Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 2397-768X

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer ; volume:6 ; number:1 ; day:24 ; month:9 ; year:2022 ; pages:1-16 ; date:12.2022
npj precision oncology ; 6, Heft 1 (24.9.2022), 1-16, 12.2022

Creator: Al-Qasem, Abeer J.
Alves, Carla L.
Ehmsen, Sidse
Tuttolomondo, Martina
Terp, Mikkel G.
Johansen, Lene E.
Vever, Henriette
Hoeg, Luna V. A.
Elias, Daniel
Bak, Martin
Ditzel, Henrik J.

Contributor: SpringerLink (Online service)

DOI: 10.1038/s41698-022-00311-6

URN: urn:nbn:de:101:1-2022121221032281338988

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:20 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Al-Qasem, Abeer J.
Alves, Carla L.
Ehmsen, Sidse
Tuttolomondo, Martina
Terp, Mikkel G.
Johansen, Lene E.
Vever, Henriette
Hoeg, Luna V. A.
Elias, Daniel
Bak, Martin
Ditzel, Henrik J.
SpringerLink (Online service)

Other Objects (12)

Regulation of CDK4

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

The role of targeting CDK4/6 in cancer immunotherapy

TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination

CDK4, pRB and E2F1: connected to insulin

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elevated expression of CDK4 in lung cancer

CDK4/6 inhibition in luminal breast cancer

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Regulation of CDK4

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

The role of targeting CDK4/6 in cancer immunotherapy

TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination

CDK4, pRB and E2F1: connected to insulin

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elevated expression of CDK4 in lung cancer

CDK4/6 inhibition in luminal breast cancer

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Regulation of CDK4

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

The role of targeting CDK4/6 in cancer immunotherapy

TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination

CDK4, pRB and E2F1: connected to insulin

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elevated expression of CDK4 in lung cancer

CDK4/6 inhibition in luminal breast cancer

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Regulation of CDK4

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

The role of targeting CDK4/6 in cancer immunotherapy

TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination

CDK4, pRB and E2F1: connected to insulin

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elevated expression of CDK4 in lung cancer

CDK4/6 inhibition in luminal breast cancer

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Regulation of CDK4

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

The role of targeting CDK4/6 in cancer immunotherapy

TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination

CDK4, pRB and E2F1: connected to insulin

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elevated expression of CDK4 in lung cancer

CDK4/6 inhibition in luminal breast cancer

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Regulation of CDK4

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

The role of targeting CDK4/6 in cancer immunotherapy

TEX19 increases the levels of CDK4 and promotes breast cancer by disrupting SKP2-mediated CDK4 ubiquitination

CDK4, pRB and E2F1: connected to insulin

Hämatologische Toxizitäten von CDK4/6 Inhibitoren

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma

Predictors of response to CDK4/6i retrial after prior CDK4/6i failure in ER+ metastatic breast cancer

Elevated expression of CDK4 in lung cancer

CDK4/6 inhibition in luminal breast cancer

Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma

Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer

Related objects

Reset password